Related Experiment Video

Updated: Aug 21, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Protein kinase C alpha expression in breast and ovarian cancer

Michael Lahn1, Gabriele Köhler, Karen Sundell

  • 1Divison of Oncology Product Development, Lilly Research Laboratories, Eli Lilly, Indianapolis, IN 46285, USA. MichaLahn@aol.com

Oncology
|October 2, 2004
PubMed

Insights

Targeting protein kinase C alpha (PKC-alpha) may benefit breast and ovarian cancer patients, particularly those with low or negative estrogen receptor (ER) levels. Further clinical studies should assess ER status to confirm efficacy of PKC-alpha inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Targeted cancer therapies focus on specific intracellular signaling proteins like protein kinase C alpha (PKC-alpha).
  • PKC-alpha's role in cancer warrants investigation for therapeutic targeting in breast and ovarian cancers.

Purpose of the Study:

  • To review existing literature on PKC-alpha expression in breast and ovarian cancers.
  • To supplement literature review with preliminary findings from patient tumor biopsies.
  • To establish the rationale for clinical studies of PKC-alpha-targeted therapy.

Main Methods:

  • Comprehensive review of publications on PKC-alpha expression in cancer cell lines.
  • Analysis of preliminary data from PKC-alpha expression in patient tumor tissue biopsies.
  • Correlation analysis between PKC-alpha levels and estrogen receptor (ER) status.

Main Results:

  • PKC-alpha expression data from cell lines and patient tumor tissues were analyzed.
  • Preliminary findings suggest elevated PKC-alpha levels in breast cancer tissues.
  • A potential correlation was observed between high PKC-alpha and low/negative ER status in breast cancer.

Conclusions:

  • PKC-alpha may be a relevant therapeutic target in breast and ovarian cancers.
  • Estrogen receptor (ER) status is a critical factor to consider in PKC-alpha targeted therapy.
  • Future clinical trials should stratify patients by ER status to evaluate PKC-alpha inhibitor efficacy.

More Related Videos

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Cancer-Critical Genes I: Proto-oncogenes01:33

Cancer-Critical Genes I: Proto-oncogenes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...